Affymax (AFFY) vs. SIGA Technologies (SIGA) Critical Comparison
Affymax (OTCMKTS: AFFY) and SIGA Technologies (OTCMKTS:SIGA) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, earnings, risk, dividends, institutional ownership, analyst recommendations and profitability.
This table compares Affymax and SIGA Technologies’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
6.7% of SIGA Technologies shares are owned by institutional investors. 1.6% of Affymax shares are owned by insiders. Comparatively, 4.7% of SIGA Technologies shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
This is a breakdown of current ratings and recommmendations for Affymax and SIGA Technologies, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Earnings and Valuation
This table compares Affymax and SIGA Technologies’ top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|SIGA Technologies||$14.99 million||25.53||-$39.69 million||($0.53)||-9.15|
Affymax has higher earnings, but lower revenue than SIGA Technologies.
Volatility & Risk
Affymax has a beta of 1.8, suggesting that its share price is 80% more volatile than the S&P 500. Comparatively, SIGA Technologies has a beta of 0.73, suggesting that its share price is 27% less volatile than the S&P 500.
Affymax, Inc. is a biopharmaceutical company. The Company’s product OMONTYS (peginesatide) is for the treatment of anemia due to chronic kidney disease in adult patients on dialysis. OMONTYS is a synthetic, peptide-based erythropoiesis stimulating agent (ESA), designed to stimulate production of red blood cells. The Company has a collaboration to develop and commercialize peginesatide with Takeda Pharmaceutical Company Limited. In March 2012, the Food and Drug Administration (FDA) approved the Company’s product, OMONTYS.
About SIGA Technologies
SIGA Technologies, Inc. is engaged in the development and commercialization of solutions for various unmet medical needs and biothreats. The Company’s lead product is TPOXX, an orally administered antiviral drug that targets orthopoxviruses infections. TPOXX is a small-molecule drug delivered to the Strategic Stockpile under the Project BioShield Act of 2004 (Project BioShield). TPOXX is an investigational product that is not approved by the United States Food and Drug Administration (FDA) as a treatment of smallpox or any other indication. The Company relies on and uses third parties known as contract manufacturing organizations (CMOs) to procure commercial raw materials and supplies, and to manufacture TPOXX. The Company identified a lead pre-clinical drug candidate with activity against four serotypes of the virus and which has shown efficacy in a murine model of disease.
Receive News & Ratings for Affymax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Affymax and related companies with MarketBeat.com's FREE daily email newsletter.